Comparing the current results to its competitors, Inmed Pharmaceuticals Inc reported Revenue decrease in the 4 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 2.02 %, recorded in the same quarter.
Inmed Pharmaceuticals Inc's Comment on Competition and Industry Peers
The company protects its intellectual property through patents, trade secrets, and process know-how. While it cannot patent naturally occurring individual cannabinoids, it pursues patents on novel methods involving cannabinoids, delivery technology, and formulations aimed at enhancing drug safety and efficacy. Competitors identified in company filings include BayMedica, BioVectra, CB Therapeutics, Cellibre, Cronos, Ginkgo Bioworks, Hyasynth, Intrexon, KinetoChem, Librede, Purisys, and Skye Biosciences Inc.
Publicly Traded Peers of Inmed Pharmaceuticals Inc
Zymeworks Inc Share Performance
+5.50%
30 Days
Zymeworks Inc
Profile
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Mira Pharmaceuticals Inc's business model is focused on the development and sale of pharmaceutical products, with a particular emphasis on research and innovation in the healthcare industry.
Milestone Pharmaceuticals Inc. is a pharmaceutical company that focuses on developing and commercializing innovative therapies for cardiovascular diseases. Their business model revolves around identifying unmet medical needs in the cardiovascular space and leveraging their expertise in drug development to create novel treatments. By conducting rigorous research, clinical trials, and collaborations, Milestone Pharmaceuticals aims to bring effective and safe medications to market, positively impacting patients' lives.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Sources:
Inmed Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Inmed Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
